Back to News
AI
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
PRNewswire·July 27, 2026·1 min read
From the source
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the …
The full text couldn't be loaded here (the source may require a subscription).
View original at PRNewswireKeep reading
Trap Created by Professor Sparks Debate on AI Use in Universitiesextra.globo.com · 1h agoHow AI turned Steve Penk’s radio wind-up calls into a video series - TVBEuropetvbeurope.com · 1h agoGyeongnam Education Office Analyzes Domestic and International Education Policy Trendsidomin.com · 1h agoAI Debt Became the 'Incentivized Debenture of the World'valor.globo.com · 2h ago
Was this useful?